The Valley Desk

ArticleFrontiers in immunologyPublished

Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling

22 of 36 authors shown in byline order.

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Frontiers in immunology
Published
Subject terms
Monocytes; Myeloid Cells; Humans; Psoriasis; Receptors, IgG; Antibodies, Monoclonal; Signal Transduction; Protein Binding; Interleukin-23; Interleukin-23 Subunit p19; Antibodies, Monoclonal, Humanized; IL-23
PubMed ID
40145093
PubMed Central ID
PMC11937023
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal